Terns Stock Analysis

TERN -  USA Stock  

USD 16.25  0.65  4.17%

The latest slide in stock price created some momentum for institutional investors as it was traded today as low as 15.35 and as high as 16.82 per share. The company executives have failed to build on market volatilities in May. However, diversifying your overall positions with Terns Pharmaceuticals may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.71. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Terns Pharmaceuticals partners.
Additionally, take a look at World Market Map.

Search Stock Analysis 

 
Refresh
The Terns Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Terns Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Terns stock analysis module also helps to analyze the Terns Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Terns Stock Analysis Notes

About 51.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Terns Pharmaceuticals had a split on the 4th of November 2013. Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California. Terns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 30 people. To find out more about Terns Pharmaceuticals contact the company at 650 525 5535 or learn more at http://www.ternspharma.com.

Terns Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Terns Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Terns Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Terns Pharmaceuticals generates negative expected return over the last 90 days
Terns Pharmaceuticals has high historical volatility and very poor performance
Net Loss for the year was (29.35 M).
Terns Pharmaceuticals currently holds about 74.85 M in cash with (29.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98.
Latest headline from www.benzinga.com: The Daily Biotech Pulse Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO - Benzinga

Terns Pharmaceuticals Thematic Classifications

In addition to having Terns Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Israel Wall Street IdeaIsrael Wall Street
Large Israel companies traded on major USA exchanges

Terns Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Terns Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Terns Pharmaceuticals backward and forwards among themselves. Terns Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Terns Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Orbimed Advisors LlcCommon Shares3.8 M83.4 M
Fmr LlcCommon Shares2.9 M63.5 M
Vivo Capital LlcCommon Shares2.7 M58.9 M
Deerfield Management Company Lp Series CCommon Shares2.3 M51.6 M
Suvretta Capital Management LlcCommon Shares1.1 M24.8 M
Matthews International Capital Management LlcCommon Shares1.1 M23.6 M
Antara Capital LpCommon Shares751.8 K16.3 M
Note, although Terns Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Terns Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 408.28 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Terns Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Terns Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (39.83) % which means that it has lost $39.83 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (68.73) %, meaning that it created substantial loss on money invested by shareholders. Terns Pharmaceuticals management efficiency ratios could be used to measure how well terns pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 20th of June, Terns Pharmaceuticals has the coefficient of variation of (1,613), and Risk Adjusted Performance of (0.030229). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Terns Pharmaceuticals, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Terns Pharmaceuticals, which can be compared to its competition. Please validate Terns Pharmaceuticals information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Terns Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 16.25 per share. Given that Terns Pharmaceuticals has jensen alpha of (0.39), we advise you to double-check Terns Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.

Terns Pharmaceuticals Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Terns Pharmaceuticals price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator. View also all equity analysis or get more info about mesa adaptive moving average overlap studies indicator.

Terns Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Terns Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Terns Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Terns Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Terns Pharmaceuticals Technical and Predictive Indicators

Terns Pharmaceuticals Forecast Models

Terns Pharmaceuticals time-series forecasting models is one of many Terns Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Terns Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Terns Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Terns Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Terns shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Terns Pharmaceuticals. By using and applying Terns Stock analysis, traders can create a robust methodology for identifying Terns entry and exit points for their positions.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California. Terns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Terns Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module
Additionally, take a look at World Market Map. Note that the Terns Pharmaceuticals information on this page should be used as a complementary analysis to other Terns Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Terns Pharmaceuticals Stock analysis

When running Terns Pharmaceuticals price analysis, check to measure Terns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Terns Pharmaceuticals is operating at the current time. Most of Terns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Terns Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Terns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Terns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Terns Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.